Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy Subjects
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
Rivaroxaban is a direct oral anticoagulant that target specifically activated factor X.
Bleeding events related to rivaroxaban are the consequence of physiopathologic,
pharmacokinetic issues or poisoning. Few results are available on the use of activated
charcoal in rivaroxaban poisoning. Moreover, a recent study, in healthy subjects, shows that
activated charcoal can reduce significantly exposition to apixaban (a direct oral
anticoagulant of the same class). The objective of this study is to evaluate the effect of
activated charcoal on rivaroxaban pharmacokinetics. It corresponds to a randomised open trial
with an incomplete cross over design (3 occasions). It will enrol 12 healthy subjects. Four
treatments modalities will be studied: rivaroxaban alone and rivaroxaban with activated
charcoal administrated 2, 4 or 8 hours after rivaroxaban administration.